STOCK TITAN

Sarepta Therapeutics, (SRPT) Debt by Year

SRPT NASDAQ

Sarepta Therapeutics,, Inc. carried $829.0M in long-term debt against $801.3M in cash and equivalents at the end of fiscal year 2025. Long-term debt fell 27.1% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Sarepta Therapeutics,, Inc. has filed alongside them.

FY2025 annual
Long-Term Debt $829.0M
Cash & Equivalents $801.3M
YoY -27.1%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

SRPT Debt & Cash by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY12FilingFY1110-K
Long-Term Debt$829.0M-27.1%$1.1B-8.1%$1.2B-19.8%$1.5B+174.0%$563.7MN/AN/A$420.6M-2.4%$431.1M+2339.7%$17.7M-34.2%$26.8M+1718.3%$1.5M-6.3%$1.6M-5.5%$1.7M-5.1%$1.8M
Cash & Equivalents$801.3M-27.4%$1.1B+157.5%$428.4M-55.7%$966.8M-54.3%$2.1B+40.8%$1.5B+79.9%$835.1M+125.2%$370.8M-38.2%$599.7M+389.9%$122.4M+52.4%$80.3M+9.2%$73.6M-71.4%$257.0M+36.9%$187.7M+370.3%$39.9M

SRPT Debt & Cash by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'25FilingQ1'25FilingQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Long-Term Debt$857.4M+510.2%$847.6M$838.2M$829.0M-27.1%$140.5M-88.6%N/AN/A$1.1B-8.1%$1.2B-0.7%$1.2B-0.7%$1.2B+0.4%$1.2B-19.8%
Cash & Equivalents$472.8M-22.9%$571.1M+11.9%$464.4M+92.8%$801.3M-27.4%$613.1M+209.9%$510.6M+33.1%$240.9M-43.6%$1.1B+157.5%$197.9M-63.5%$383.6M-55.0%$427.3M-51.0%$428.4M-55.7%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More Sarepta Therapeutics,, Inc. financials

Frequently Asked Questions

Sarepta Therapeutics,, Inc. carried $829.0M in long-term debt against $801.3M in cash and equivalents at the end of fiscal year 2025.

Sarepta Therapeutics,, Inc. (SRPT) long-term debt fell by 27.1% year over year, from $1.1B to $829.0M in fiscal year 2025.

Across the 15 fiscal years this page covers, Sarepta Therapeutics,, Inc. (SRPT) long-term debt went from $1.8M in fiscal year 2011 to $829.0M in fiscal year 2025.

Sarepta Therapeutics,, Inc. (SRPT) reported $857.4M in long-term debt in Q3 2026. This represents an increase of 510.2% from the same quarter a year earlier.

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Sarepta Therapeutics,, Inc. (SRPT) reported on that line in every period on record.